Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
α-Methylacetylfentanyl is a synthetic opioid analgesic and a structural analog of fentanyl. It acts as an agonist at the mu-opioid receptor, producing effects similar to those of fentanyl, including potent analgesia, euphoria, sedation, and significant risk of respiratory depression. Like other fentanyl analogs, it has been associated with severe toxicity and fatal overdoses. α-Methylacetylfentanyl was briefly sold illicitly in the early 1980s before being classified as a Schedule I controlled substance in many jurisdictions due to its high abuse potential and lack of accepted medical use[2][3][4]. Its synthesis is similar to that of α-methylfentanyl but uses acetic anhydride instead of propionic anhydride[2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on α-methylacetylfentanyl.